Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving β-blockers: insights from the BEST trial.

[1]  A. Coats,et al.  Ethics in the authorship and publishing of scientific articles , 2010 .

[2]  G. Filippatos,et al.  Effects of Right Ventricular Ejection Fraction on Outcomes in Chronic Systolic Heart Failure , 2010, Circulation.

[3]  L. Lazzeroni,et al.  An &agr;2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the &bgr;-Blocker Bucindolol in Chronic Heart Failure , 2010, Circulation. Heart failure.

[4]  Himanshu Gupta,et al.  Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. , 2008, Journal of the American College of Cardiology.

[5]  S. Hunt,et al.  Right Ventricular Function in Cardiovascular Disease, Part II: Pathophysiology, Clinical Importance, and Management of Right Ventricular Failure , 2008, Circulation.

[6]  G. Germano,et al.  EANM/ESC guidelines for radionuclide imaging of cardiac function , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Humbert,et al.  Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. , 2006, Gastroenterology.

[8]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[9]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[10]  C. Yancy,et al.  Gender differences in advanced heart failure: insights from the BEST study. , 2003, Journal of the American College of Cardiology.

[11]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[12]  N. Aiyar,et al.  Bucindolol Displays Intrinsic Sympathomimetic Activity in Human Myocardium , 2002, Circulation.

[13]  R. Schwinger,et al.  Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium , 2001, British journal of pharmacology.

[14]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[15]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[16]  H. Samady,et al.  Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[17]  T. R. I. Nvestigators.  A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[18]  L. Tavazzi,et al.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[19]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[20]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[21]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[22]  M. Mathier,et al.  Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. , 1995, Journal of the American College of Cardiology.

[23]  Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. , 1995, The American journal of cardiology.

[24]  J. Cruickshank.  The xamoterol experience in the treatment of heart failure. , 1993, The American journal of cardiology.

[25]  R. Hershberger,et al.  Mechanism of Action of Bucindolol in Human Ventricular Myocardium , 1990, Journal of cardiovascular pharmacology.

[26]  M. Wilén,et al.  Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. , 1984, The American journal of cardiology.

[27]  A. Hakki,et al.  Right ventricular function: methodologic and clinical considerations in noninvasive scintigraphic assessment. , 1984, Journal of the American College of Cardiology.